These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25116835)

  • 1. Plasma DYRK1A as a novel risk factor for Alzheimer's disease.
    Janel N; Sarazin M; Corlier F; Corne H; de Souza LC; Hamelin L; Aka A; Lagarde J; Blehaut H; Hindié V; Rain JC; Arbones ML; Dubois B; Potier MC; Bottlaender M; Delabar JM
    Transl Psychiatry; 2014 Aug; 4(8):e425. PubMed ID: 25116835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.
    Janel N; Alexopoulos P; Badel A; Lamari F; Camproux AC; Lagarde J; Simon S; Feraudet-Tarisse C; Lamourette P; Arbones M; Paul JL; Dubois B; Potier MC; Sarazin M; Delabar JM
    Transl Psychiatry; 2017 Jun; 7(6):e1154. PubMed ID: 28632203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
    Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
    Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
    Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
    Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
    Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
    Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.
    Ryoo SR; Jeong HK; Radnaabazar C; Yoo JJ; Cho HJ; Lee HW; Kim IS; Cheon YH; Ahn YS; Chung SH; Song WJ
    J Biol Chem; 2007 Nov; 282(48):34850-7. PubMed ID: 17906291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
    Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
    Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
    Dowjat K; Adayev T; Wojda U; Brzozowska K; Barczak A; Gabryelewicz T; Hwang YW
    J Alzheimers Dis; 2019; 72(4):1059-1075. PubMed ID: 31683476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
    Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
    Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation.
    Lee YH; Im E; Hyun M; Park J; Chung KC
    J Biol Chem; 2021; 296():100245. PubMed ID: 33380426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.
    Vázquez-Higuera JL; Sánchez-Juan P; Rodríguez-Rodríguez E; Mateo I; Pozueta A; Frank A; Sastre I; Valdivieso F; Berciano J; Bullido MJ; Combarros O
    BMC Med Genet; 2009 Dec; 10():129. PubMed ID: 19995442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
    Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
    Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
    Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.